newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the investigator-led Phase II trial titled "Prevention Of NephroToxin Induced